Abstracts tagged "Cardiovascular"

Abstract Number: 2585 • ACR Convergence 2025
The effect of prophylactic colchicine use on gene expression in gout
Austin Wheeler¹, Guanqi Lu², Ana Vazquez³, Jeffrey Edberg⁴, Angelo Gaffo⁵, Tate Johnson¹, Michael Duryee¹, James O'Dell¹, Jeff Newcomb¹, Michael Pillinger⁶, Robert Terkeltaub⁷, Ryan Ferguson⁸, Mary Brophy⁸, Tuhina Neogi⁹, Bryant England¹, Ted Mikuls¹, Tony Merriman¹⁰ and Richard Reynolds⁴, ¹University of Nebraska Medical Center, Omaha, NE, ²Michigan State University, East Lansing, MI, ³Michigan State University, Miami, FL, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Rheumatology and Clinical Immunology, University of Alabama, Birmingham, AL, USA; Birmingham VA Medical Center, Birmingham, AL, USA, Birmingham, AL, ⁶New York University Grossman School of Medicine, New York,, NY, ⁷Retired, San Diego, CA, ⁸VA Cooperative Studies Program Coordinating Center, Boston, MA, ⁹Boston University School of Medicine, Boston, MA, ¹⁰University of Alabama at Birmingham, Homewood, AL
Background/Purpose: Colchicine is recommended for the treatment and prophylaxis of gout flares and approved for secondary prevention of ischemic cardiovascular disease (CVD). While its primary…
Abstract Number: 2245 • ACR Convergence 2025
Add-on of Coronary Artery Calcium Score Significantly Improves the Risk Prediction of Cardiovascular Diseases in Patients with Rheumatoid Arthritis: From a Real-world Cohort Study
Yao-Wei Zou, Ying Yang, Zhi-Ming Ouyang, Ran Shi, Tao Wu, Kui-Min Yang, Jian-Da Ma and Lie Dai, Department of Rheumatology and Immunology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China (People's Republic)
Background/Purpose: Cardiovascular diseases (CVD) are the first cause of death in patients with rheumatoid arthritis (RA). The guidelines recommend risk prediction in all RA patients.…
Abstract Number: 1743 • ACR Convergence 2025
Comparative assessment of cardiovascular risk and its predictors in a large cohort of young adults with juvenile systemic lupus erythematosus and juvenile dermatomyositis
Jiangning Li, Shreya Doddi, Tharuni Mailoo and Coziana Ciurtin, University College London, London, United Kingdom
Background/Purpose: Juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM) are associated with chronic inflammation that can accelerate atherosclerosis. There is no specific guidance regarding…
Abstract Number: 1397 • ACR Convergence 2025
Cardiovascular And Cerebrovascular Risk In Sjögren’s Disease: Results From A Prospective Multicenter Cohort.
Olga Rusinovich¹, Zulema Plaza², Monica Fernandez Castro³, Jose Rosas Gómez de Salazar⁴, Victor Martinez-Taboada⁵, Alex Olive⁶, Raúl Menor Almagro⁷, Belén Serrano-Benavente⁸, Judit Font-Urgelles⁹, Angel Garcia-Aparicio¹⁰, Sara Manrique-Arija¹¹, Jesús Alberto Garcia Vadillo¹², Ruth Lopez-Gonzalez¹³, Javier Narváez¹⁴, Maria Beatriz Rodriguez¹⁵, Carlos Galisteo¹⁶, Jorge Juan Gonzalez Martin¹⁷, Paloma Vela Casasempere¹⁸, Cristina Bohorquez¹⁹, MARIA CELIA ERAUSQUIN ARRUABARRENA²⁰, Beatriz Paredes-Romero²¹, Leyre Riancho-Zarrabeitia²², Sheila Melchor Diaz²³, José María Pego-Reigosa²⁴, Sergi Herdia²⁵, Clara Moriano²⁶, Mª Angeles Blazquez Cañamero²⁷, Paula Estrada-Alarcón²⁸, Enrique Judez²⁹, Nerea Alcorta-Lorenzo³⁰, Consuelo Ramos Giraldez³¹, Fernando Sánchez-Alonso³² and Jose Luis Andreu³³, ¹Puerta de Hierro University Hospital, Boadilla del Monte, Spain, ²Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ³PUERTA DE HIERRO HOSPITAL, Madrid, Spain, ⁴Hospital Marina Baixa, PALMA DE MALLORCA, Spain, ⁵Facultad de Medicina. Universidad de Cantabria, Santander, Spain, ⁶Solo practice, Barcelona, Spain, ⁷Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ⁸Hospital Gregorio Marañon, Madrid, Spain, ⁹Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ¹⁰Hospital Universitario de Toledo, Toledo, Spain, ¹¹Hospital Regional Universitario Málaga, Malaga, Spain, ¹²Hospital Universitario La Princesa, Madrid, Spain, ¹³Zamora Health Complex, Salamanca, Spain, ¹⁴Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁵Canarias University Hospital, La Laguna- Tenerife, Spain, ¹⁶Hospital Parc Taulí, Sabadel, Sabadel, Spain, ¹⁷HM Sanchinarro Univeristary Hospital, Madrid, Spain, ¹⁸Hospital General Universitario Alicante, Alicante, Comunidad Valenciana, Spain, ¹⁹La Paz University Hospital, Alcalá De Henares, Spain, ²⁰Dr Negrin University Hospital, Ls Palmas, Spain, ²¹Hospital Universitario Infanta Sofía;Universidad Europea de Madrid. Faculty of Medicine, Health and Sports. Department of Medicine; FIIB HUIS-HUHEN, San Sebastian de los Reyes, Spain, ²²Rheumatology Department. Hospital Sierrallana, Torrelavega, Spain, ²³¹² de Octubre University Hospital, Madrid, Spain, ²⁴Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²⁵Complex Hospitalari Moisès Broggi, Barcelona, Spain, ²⁶Hospital León, LEON, Castilla y Leon, Spain, ²⁷Hospital Ramon y Cajal, Madrid, Spain, ²⁸Complex Universitari Hospital Moisès Broggi, Barcelona, Spain, ²⁹Albacete University Hospital, Albacete, Spain, ³⁰Rheumatology Department, Donostia University Hospital., San Sebastian, Spain, ³¹Hospital Universitario Virgen de Valme, Servicio de Reumatología, Seville, Spain, ³²Sociedad Española de Reumatología, Madrid, Spain, ³³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: To evaluate the incidence of cardiovascular and cerebrovascular events (CVEs) in patients with Sjögren’s Disease (SjD), focusing on major adverse cardiovascular events (MACE), defined…
Abstract Number: 0677 • ACR Convergence 2025
Increased incidence of sudden cardiac death in systemic sclerosis: estimate & correlates.
Jessica Fairley¹, Elizabeth Paratz², Dylan Hansen³, Susanna Proudman⁴, Joanne Sahhar⁵, Gene-Siew Ngian⁶, Diane Apostolopoulos⁶, Jennifer Walker⁷, Lauren Host⁸, Wendy Stevens¹, Andre La Gerche², Mandana Nikpour⁹ and Laura Ross¹, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴The University of Adelaide, Adelaide, Victoria, Australia, ⁵Monash Health, Melbourne, Victoria, Australia, ⁶Monash University, Melbourne, Victoria, Australia, ⁷Flinders University, Adelaide, Victoria, Australia, ⁸Fiona Stanley Hospital, Perth, Victoria, Australia, ⁹University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia
Background/Purpose: The incidence of sudden cardiac death (SCD) is suspected to be increased in systemic sclerosis (SSc). However, data describing SCD incidence in SSc are…
Abstract Number: 0450 • ACR Convergence 2025
The Fibrosis-4 Index (FIB-4) Correlates with Cardiovascular Risk and Insulin Resistance in Patients with Rheumatoid Arthritis
Jose Marí Viotti-Serra¹, Elena Heras-Recuero², Juan C. Quevedo-Abeledo³, Miguel A. González-Gay⁴ and Ivan Ferraz Amaro⁵, ¹Hospital Universitario de Canarias, Tenerife, Canarias, Spain, ²Fundación Jiménez Díaz, Madrid, Madrid, Spain, ³Hospital Doctor Negrín, Las Palmas de Gran Canaria, Canarias, Spain, ⁴Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁵Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain
Background/Purpose: The Fibrosis-4 index (FIB-4), a non-invasive tool for assessing liver fibrosis, has been linked to cardiovascular (CV) risk in the general population. This is…
Abstract Number: 0024 • ACR Convergence 2025
Biobank-scale genetic mapping identifies the shared genetic landscape of rheumatic and cardiovascular disease
Daniel Panyard¹, Daniel Li², Pik Fang Kho², Rodrigo Guarischi-Sousa³, Jiayan Zhou², Austin Hilliard⁴, Christie Bartels⁵, Philip Tsao² and Themistocles Assimes², ¹Stanford University, Sunnyvale, CA, ²Stanford University, Palo Alto, CA, ³Palo Alto Veterans Institute for Research, Palo Alto, CA, ⁴VA Palo Alto Health Care, Palo Alto, CA, ⁵University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: Patients with rheumatic conditions are at increased risk for cardiovascular (CV) problems, striking on average a decade before peers and conferring substantial morbidity and…
Abstract Number: 2569 • ACR Convergence 2025
Performance of the PREVENT Heart Failure General Population Risk Score in Patients with Rheumatoid Arthritis
Ilana Usiskin¹, Katherine Zhong², Ying Qi³, Lauren rusnak¹, Andrew Cagan¹, Yumeko Kawano¹, Tianrun Cai¹, Daniel Solomon⁴, Jennifer Ho⁵, Brittany Weber⁶ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Short Hills, NJ, ³Brigham and Women’s Hospital, Boston, ⁴Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital, Boston, MA, ⁵Beth Israel Deaconess Medical Center, Boston, MA, ⁶Brigham and Women's Hospital, DEDHAM, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of heart failure (HF) compared to the general population, and HF with preserved ejection fraction…
Abstract Number: 2221 • ACR Convergence 2025
Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus
Rashmi Dhital¹, Rebecca Baer² and Christina Chambers³, ¹Vanderbilt University Medical Center, Brentwood, TN, ²University of California San Diego, San Diego, CA, ³University of California, San Diego, La Jolla, CA
Background/Purpose: Pregnant individuals with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular events (CVEs) as well as adverse pregnancy outcomes (APOs). While racial…
Abstract Number: 1716 • ACR Convergence 2025
The frequency and impact of cardiovascular disease in systemic lupus erythematosus: a Nationwide, matched case-control study.
Jessica Fairley¹, Laura Ross¹, Elizabeth Paratz², Penelope McKelvie³, Simin Daneshvar³, Shereen Oon⁴, Dylan Hansen³, Wendy Stevens¹, Andre La Gerche² and Mandana Nikpour⁵, ¹The University of Melbourne, Melbourne, Victoria, Australia, ²St Vincent's Institute of Medical Research, Melbourne, Victoria, Australia, ³St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia, ⁴St Vincent’s Hospital Melbourne, Melbourne, Victoria, Australia, ⁵University of Sydney School of Public Health and Department of Rheumatology, Royal Prince Alfred Hospital, Sydney, Victoria, Australia
Background/Purpose: Cardiovascular disease is the leading cause of death in systemic lupus erythematosus (SLE).1 Whilst histopathology remains the gold standard for establishing the pathogenesis of…
Abstract Number: 1334 • ACR Convergence 2025
Cardiac Biomarkers and Prediction of Major Cardiovascular Events in Rheumatoid Arthritis: Results from the ESPOIR Cohort
manon lesturgie¹, Fiona Oudart¹, Anne Cauvet², Virginie Gonzalez², Bruno Fautrel³, Arnaud Constantin⁴, Nathalie Rincheval⁵, Yannick Allanore⁶ and Jérôme Avouac⁷, ¹INSERM U¹⁰¹⁶, Paris, France, ²INSERMU¹⁰¹⁶, Paris, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Hôpital Pierre-Paul Riquet, CHU Purpan, Toulouse, France, ⁵Institut de Recherche Clinique EA²⁴¹⁵, Université de Montpellier, Département de Statistiques, Montpellier, France, ⁶Université Paris Cité, Paris, France, ⁷Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with rheumatoid arthritis (RA) experience premature mortality, largely due to cardiovascular (CV) disease. The increased CV risk is due to both the underlying…
Abstract Number: 0671 • ACR Convergence 2025
The Gut-Heart Axis in Systemic Sclerosis: Evidence from the GENISOS cohort
Francesca Romana Di Ciommo¹, Ashish Balar², Subhash Kulkarni³, Aidan K Strother², Michael Hughes⁴, Brian Skaug⁵, Maureen Mayes⁶, Shervin Assassi⁷, Ali Y Ayla² and Zsuzsanna McMahan⁸, ¹La Sapienza University of Rome, Rome, Italy, ²UTHealth Houston, Houston, TX, ³BIDMC, Boston, MA, ⁴Division of Musculoskeletal and Dermatological Sciences, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK, Manchester, England, United Kingdom, ⁵UTHealth Houston Division of Rheumatology, Houston, TX, ⁶UT Health Houston Division of Rheumatology, Houston, TX, ⁷Division of Rheumatology, UTHealth Houston, Houston, Texas, USA, Houston, TX, ⁸UT Health Houston, Houston, TX
Background/Purpose: Cardiac manifestations significantly impact the prognosis of patients with systemic sclerosis (SSc), underscoring the need for early risk stratification. While gastrointestinal (GI) symptoms are…
Abstract Number: 0445 • ACR Convergence 2025
GLP-1 Receptor Agonists Reduce Mortality and Cardiovascular Events in Patients with Rheumatoid Arthritis
Giorgos Loizidis and Ross summer, Thomas Jefferson University, Philadelphia, PA
Background/Purpose: Obesity significantly increases cardiovascular morbidity and mortality in rheumatoid arthritis (RA), yet effective strategies for managing obesity-related risks in this population remain limited. Glucagon-like…
Abstract Number: 0581 • ACR Convergence 2025
Effects of Apremilast on Body Mass Index, Weight, and HbA1c as Cardiometabolic Outcomes in Patients With Early Oligoarticular Psoriatic Arthritis in the FOREMOST Study
Philip J. Mease¹, Álvaro González Cantero², Jennifer Soung³, April Armstrong⁴, Joseph F Merola⁵, Fabian Proft⁶, Laure Gossec⁷, Dafna D. Gladman⁸, Laura Coates⁹, Lichen Teng¹⁰, Jimena Vázquez¹¹, Cynthia Deignan¹² and Arthur Kavanaugh¹³, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Dermatology, Ramón y Cajal University Hospital, Madrid, Spain, ³Southern California Dermatology, Inc, Santa Ana, CA, USA, Santa Ana, ⁴University of California Los Angeles, Los Angeles, ⁵Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX, ⁶Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁷Sorbonne Université, Pitié Salpêtrière Hospital, Paris, France, ⁸Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁹Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, England, United Kingdom, ¹⁰Amgen Inc., Thousand Oaks, ¹¹Amgen Inc., Thousand Oaks, CA, ¹²Amgen, Inc., Agoura Hills, CA, ¹³University of California, San Diego, School of Medicine, San Diego, CA
Background/Purpose: The prevalence of cardiometabolic diseases, including obesity and diabetes, is higher in patients with psoriatic arthritis (PsA) than those without PsA.1,2 Metabolic syndrome is…
Abstract Number: 0140 • ACR Convergence 2024
Estimation of 10-year Cardiovascular (CV) Risk and Traditional CV Risk Factors Distribution in Patients with Rheumatoid Arthritis from Three Italian Macro-areas
Fabiola Atzeni¹, Fabio Cacciapaglia², Elena Bartoloni Bocci³, Matteo Piga⁴, Garifallia Sakellariou⁵, Ombretta Viapiana⁶, Alessandro Giollo⁷, SIMONE PARISI⁸, Maria Sole Chimenti⁹, Ennio Giulio Favalli¹⁰, Addolorata Corrado¹¹, Eleonora Celletti¹², Ivan Giovannini¹³, Serena Guiducci¹⁴, Elisa Gremese¹⁵, Andreina Manfredi¹⁶, Francesca Romana Spinelli¹⁷ and Gian Luca Erre¹⁸, and "Cardiovascular Obesity and Rheumatic DISeaases" Study Group of the Italian Society of Rheumatology, ¹University of Messina, Italy, Messina, Italy, ²Rheumatology Unit DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ³Rheumatology Unit. Department of Medicine, Perugia, Perugia, Italy, ⁴Rheumatology Unit - Department of Medical Sciences and Public Health, University of Cagliari, Monserrato, Italy, ⁵Department of Internal Medicine and Medical Therapy, University of Pavia, and Istituti Clinici Scientifici Maugeri IRCCS Pavia,, Pavia, Italy, ⁶Rheumatology Unit, University of Verona, Verona, Italy, ⁷Azienda Ospedale Università Padova, Padova, Padua, Italy, ⁸Rheumatology Unit, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, TURIN, Italy, ⁹Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Roma, Italy, ¹⁰ASST Gaetano Pini-CTO, Milan, Lombardia, Italy, ¹¹Rheumatology Unit, University of Foggia, Foggia, Italy, ¹²Medical Clinic, SS. Annunziata Hospital of Chieti, Department of Medicine and Science of Aging, G. D'Annunzio University of Chieti-Pescara, Chieti, Italy, ¹³Azienda Sanitaria Universitaria Friuli Centrale, Udine, Udine, Italy, ¹⁴University of Florence, Pistoia, Italy, ¹⁵Catholic University of the Sacred Heart, Rome, Rome, Italy, ¹⁶University of Modena and Reggio Emilia, Modena, ¹⁷Sapienza University of Rome, Rome - Italy, Roma, Rome, Italy, ¹⁸Rheumatology Unit - University of Sassari, Sassari, Italy
Background/Purpose: Geographic origins can significantly impact people’s health, particularly in Italy, where regional health disparities are among the most pronounced [1]. Rheumatoid arthritis (RA) is…

« Previous Page
1
…
5
6
7
8
9
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].